🇺🇸 FDA
Patent

US 11964985

Anti-cancer compounds targeting Ral GTPases and methods of using the same

granted A61KA61K31/351A61K31/4162

Quick answer

US patent 11964985 (Anti-cancer compounds targeting Ral GTPases and methods of using the same) held by The Regents of the University of Colorado, a Body Corporate expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/351, A61K31/4162, A61K31/437, A61K31/505